Skip to search formSkip to main contentSkip to account menu

DIMS0150

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

DNA

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
P080 IL-10 induction properties of the TLR-9 agonist cobitolimod - a candidate for treatment of active ulcerative colitis in late stage of clinical development.
s of the 12th Congress of ECCO – European Crohn’s and Colitis Organisation S117 that both genotype and phenotype influenced the… 
2016
2016
Mo1785 Histopathological Response and Remission After Dual Topical Application of the Toll-Like-Receptor 9 Agonist DIMS0150 in Patients With Moderate to Severe Ulcerative Colitis
2016
2016
Mo1778 The Toll-Like-Receptor 9 Agonist DIMS0150 Demonstrates Therapeutic Efficacy for the Patient Reported Outcome Measures PRO-2 and Clinpro in Moderate to Severe Active Ulcerative Colitis
2015
2015
Tu1326 Topical Administration of the Toll-Like Receptor 9 Agonist DIMS0150 Provides Evidence for Efficacy in Moderate to Severe Ulcerative Colitis Treated in the Clinical Study Collect
2014
2014
Treatment of Ulcerative Colitis Patients by Local Application of the Toll like Receptor-9 Agonist DIMS0150
Background and aim: The Toll like receptor 9 (TLR9) has over the years received growing interest as a potential point of… 
2014
2014
Tu1706 The TLR-9 Agonist DIMS0150 Leads to the Induction of IL-10 Positive Mucosal Cells in Ulcerative Colitis Patients
2014
2014
P018 The anti-inflammatory cytokine IL-10 is an important mediator of the action of the TLR-9 agonist DIMS0150
2014
2014
DOP004 Induction of IL-10 positive cells in the colon mucosa of ulcerative colitis patients by the TLR-9 agonist DIMS0150
2013
2013
89 Sustained Clinical Response and Remission Achieved in Moderately Severe Ulcerative Colitis Patients by Local Application of the TLR-9 Agonist Dims0150
2013
2013
P361 Sustained clinical response and remission achieved in moderately severe ulcerative colitis patients by local application of the TLR-9 agonist DIMS0150
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)